Balanced news tone
News Sentiment
MRK sentiment intelligence
Merck KGaA news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
80/100 classification confidence.
directly relevant articles
high-authority source matches
-4.1% over one week, +4.8% over four weeks, trend active, and near fair-value range.
Merck: 'Strong Buy' Lipfendra FDA First And Continued Oncology Expansions (NYSE:MRK)
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Merck: 'Strong Buy' Lipfendra FDA First And Continued Oncology Expansions (NYSE:MRK)
- Tone
- Positive 82/100
- Event
- Market update
- Published
- 17 Jul 2026 19:30
- Source
- Seeking Alpha
Merck Reportedly Goes To Bat In Takeover Battle. But Genomics Stock Reverses.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jul 2026 17:01
- Source
- Investor's Business Daily
New Cholesterol Pill, Earnings Growth Boost Merck Shares
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 17 Jul 2026 12:40
- Source
- FXEmpire
Personalis draws takeover interest from Merck (PSNL:NASDAQ)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jul 2026 12:38
- Source
- Seeking Alpha
The Real Question Buried Inside Merck Stock's Premium Price
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jul 2026 12:31
- Source
- Trefis
Guggenheim reiterates Merck stock rating on Lipfendra approval
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 17 Jul 2026 12:08
- Source
- Investing.com
Merck Stock Analysis: FDA Boost Sparks Bullish Rally Outlook
- Tone
- Positive 66/100
- Event
- Guidance
- Published
- 17 Jul 2026 10:49
- Source
- The Cryptonomist
Merck Snags A First-Ever Approval; Shares Pop
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 16 Jul 2026 20:07
- Source
- Investor's Business Daily
Merck (MRK) Stock Sees Modest Fair Value Lift As Analysts Raise Targets
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 16 Jul 2026 16:12
- Source
- Market source
Why Merck & Co. (MRK) Stock Is Up Today
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jul 2026 15:36
- Source
- Quiver Quantitative
Dow Jones' Merck Scores A Win With Cancer Smart Bomb
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jul 2026 20:17
- Source
- Investor's Business Daily
Merck (MRK) Stock Looks Like A Bargain At This Price
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2026 13:09
- Source
- Market source
Merck (MRK) Stock Sinks As Market Gains: Here's Why
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 10 Jul 2026 21:45
- Source
- Market source
MRK, NEUP Stocks Drop As Merck Scraps Another Alzheimer’s Drug Trial Under Neuphoria Partnership
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 01 Jul 2026 07:00
- Source
- Market source
Merck (MRK) Stock Weighs Strong Rally Against Mixed Valuation Signals
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 26 Jun 2026 07:00
- Source
- Market source
Merck KGaA to acquire Bio-Techne in $11.3 billion deal
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 26 Jun 2026 07:00
- Source
- qz.com
Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 07:00
- Source
- Market source
Stock Market Today, June 25: Bio-Techne Surges After Merck KGaA Announces $73-Per-Share Cash Acquisition Offer
- Tone
- Positive 66/100
- Event
- Deals and strategy
- Published
- 25 Jun 2026 07:00
- Source
- Market source
Bio-Techne Is Today’s Top S&P 500 Stock. Germany’s Merck to Buy Company for $11.3 Billion.
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 25 Jun 2026 07:00
- Source
- Barron's
Germany's Merck to buy Bio-Techne for $11.3 billion
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 25 Jun 2026 07:00
- Source
- Yahoo! Finance Canada
Germany's Merck boosts life sciences business with $11 billion Bio-Techne deal
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 25 Jun 2026 07:00
- Source
- CNBC
Germany's Merck boosts life sciences business with $11 billion bet on Bio-Techne
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Jun 2026 07:00
- Source
- Reuters
Merck KGaA, Darmstadt, Germany, Agrees to Acquire Bio-Techne, Strengthening Leadership Position in Fast-Growing Life Sciences Markets
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Jun 2026 07:00
- Source
- PR Newswire
Germany's Merck KGaA Swoops In With $11.3 Billion Medtech Buyout
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Jun 2026 07:00
- Source
- Investor's Business Daily
Merck KGaA to Acquire Bio-Techne for $11.3B, Expanding Life Science Tools Presence
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Jun 2026 07:00
- Source
- Genetic Engineering and Biotechnology News
Germany’s Merck to Boost Lab-Tools Business With $11 Billion Bio-Techne Deal
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 25 Jun 2026 07:00
- Source
- WSJ
Merck KGaA: Bio-Techne Acquisition Improves Quality, But The Stock Seems Fully Valued (Downgrade)
- Tone
- Negative 34/100
- Event
- Deals and strategy
- Published
- 25 Jun 2026 07:00
- Source
- Seeking Alpha
Merck (MRK) Stock Gets New Outperform Rating from CICC
- Tone
- Positive 66/100
- Event
- Analyst action
- Published
- 24 Jun 2026 07:00
- Source
- Market source
Merck KGaA (MKKGY): Company Profile, Stock Price, News, Rankings
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 07:00
- Source
- Fortune
Germany’s Merck KGaA Shares Jump After Guidance Lift
- Tone
- Neutral 50/100
- Event
- Guidance
- Published
- 13 May 2026 07:00
- Source
- WSJ